Zylorion

Zylorion, formerly PsiloTec Health Solutions, is a private Canadian biopharmaceutical company developing neuroplasticity-focused therapies for brain disorders. The company began with a psychedelic-therapy and mental health focus and has since repositioned around novel oral small-molecule compounds that enhance brain-derived neurotrophic factor and TrkB signaling. Its lead program, ZYL-314, is in preclinical development for early Alzheimer's disease and mild cognitive impairment, with a broader platform strategy built around additional formulations and combinations. Zylorion emphasizes scalable oral treatments, patent-protected chemistry, and neuroplasticity-based approaches for neurodegenerative and central nervous system diseases.